As of Mar 26
| -0.0078 / -1.07%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 3.50 and a low estimate of 1.25. The median estimate represents a +315.40% increase from the last price of 0.72.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.